ArticleFrontiers in oncology2019

Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors.

Nirmitha I Herath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.